爪真菌症治療の世界市場レポート 2025年

爪真菌症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で50億9,000万米ドルに成長します。予測期間の成長は、高齢化、遠隔医療の拡大、併用療法、ヘルスケアへのアクセスの増加、ライフスタイルや環境要因の変化、糖尿病有病率の増加などに起因すると考えられます。予測期間における主な動向には、皮膚科学的進歩、ドラッグデリバリーの革新、個別化治療計画、局所治療の進歩、デジタルヘルスソリューション、レーザー治療などがあります。

真菌感染症の罹患率の上昇が、今後数年間の爪真菌症治療市場の成長を牽引すると予想されます。真菌感染症は、さまざまな真菌によって引き起こされる微生物疾患で、身体のさまざまな部分に影響を及ぼし、特定の状態に至る。爪真菌症（真菌性爪感染症）は、一般的に抗真菌薬の内服や抗真菌液の外用で治療され、根本的な真菌の増殖を根絶し、健康な爪の再生を促進します。例えば、2023年9月、英国の政府機関であるUK Health Security Agencyは、SGSSが追跡した2022年のイングランドにおけるイースト菌による血流感染症（BSI）の記録症例数は2,265例であったと報告しました。酵母によるBSIの罹患率は人口10万人当たり4.0人と、2021年の3.8人からわずかに増加しました。血液検体で最も頻繁に同定された3種の酵母は、カンジダ・アルビカンス（40％）、ナカセオマイセス・グラブラタス（以前はカンジダ・グラブラータとして知られていた、29％）、カンジダ・パラプシローシス（13％）でした。このように、真菌感染症の増加が爪真菌症治療市場の成長に寄与しています。

糖尿病有病率の上昇は、当面の爪真菌症治療市場の成長を牽引する見通しです。糖尿病は、血糖値の上昇を特徴とする慢性疾患であり、爪真菌症を発症する可能性を高め、感染症のリスクを高め、治癒プロセスを遅らせる。外用療法とレーザー療法は、合併症を予防し、足の健康を増進し、最終的にその後の感染症のリスクを低減する上で重要な役割を果たします。例えば、2021年3月、ルイジアナ州を拠点とする農業研究センターであるLSU AgCenterの報告によると、2021年には米国で3,420万人を超える糖尿病患者がおり、2030年には糖尿病に罹患する世界人口が5億7,800万人に急増すると予測されています。その結果、糖尿病の蔓延が爪真菌症治療市場拡大の主要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界爪真菌症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の爪真菌症治療市場：成長率分析
• 世界の爪真菌症治療市場の実績：規模と成長, 2019-2024
• 世界の爪真菌症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界爪真菌症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の爪真菌症治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遠位舌下爪真菌症
• 白色表在性爪白癬
• 近位舌下爪真菌症
• カンジダ爪白癬
• その他のタイプ
• 世界の爪真菌症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• レーザー治療
• 光線力学療法
• 世界の爪真菌症治療市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 0～18歳
• 18歳から39歳
• 40歳から64歳
• 65歳以上
• 世界の爪真菌症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル

第7章 地域別・国別分析

• 世界の爪真菌症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の爪真菌症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 爪真菌症治療市場：競合情勢
• 爪真菌症治療市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Hetero Drugs Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sun Pharmaceutical Industries Limited
• Cadila Pharmaceuticals Ltd.
• Dr. Reddys Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Cipla Limited
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Alkem Laboratories Limited
• Jubilant Life Sciences Ltd.
• Torrent Pharmaceuticals Ltd.
• Mankind Pharma Ltd.
• Biocon Limited
• Emcure Pharmaceuticals Limited
• Alembic Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 爪真菌症治療市場2029：新たな機会を提供する国
• 爪真菌症治療市場2029：新たな機会を提供するセグメント
• 爪真菌症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Onychomycosis treatment involves medical interventions and strategies employed to address and cure onychomycosis, a fungal infection that impacts both fingernails and toenails. The management of onychomycosis typically comprises a combination of topical and oral antifungal medications, along with preventive measures aimed at reducing the risk of recurrence.

The primary forms of onychomycosis include distal sublingual onychomycosis, white superficial onychomycosis, proximal sublingual onychomycosis, candida onychomycosis, and others. Distal sublingual onychomycosis, for instance, is a fungal nail infection that affects the underside of the nail tip, often caused by dermatophyte fungi. Treatments encompass a variety of approaches, including medications, laser therapy, and photodynamic therapy, catering to different age groups, including individuals aged 0 to 18 years, 18 to 39 years, 40 to 64 years, and those aged 65 years and above. Multiple distribution channels are involved, including hospital pharmacies, retail pharmacies, and others.

The onychomycosis treatment market research report is one of a series of new reports from The Business Research Company that provides onychomycosis treatment market statistics, including onychomycosis treatment industry global market size, regional shares, competitors with a onychomycosis treatment market share, detailed onychomycosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the onychomycosis treatment industry. This onychomycosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The onychomycosis treatment market size has grown strongly in recent years. It will grow from $3.65 billion in 2024 to $3.92 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing fungal infections, aging population, public awareness, rising prevalence of onychomycosis, rising disposable incomes.

The onychomycosis treatment market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to aging population, telemedicine expansion, combination therapies, increasing access to healthcare, changing lifestyles and environmental factors, increasing prevalence of diabetes. Major trends in the forecast period include dermatological advancements, drug delivery innovations, personalized treatment plans, topical treatment advances, digital health solutions, laser therapy.

The rising incidence of fungal infections is expected to drive the growth of the onychomycosis treatment market in the coming years. Fungal infections are microbial diseases caused by various fungi, impacting different parts of the body and leading to specific conditions. Onychomycosis, or fungal nail infection, is commonly treated with oral antifungal medications or topical antifungal solutions to eradicate the underlying fungal growth and promote healthy nail regrowth. For example, in September 2023, the UK Health Security Agency, a government body in the UK, reported that there were 2,265 recorded cases of bloodstream infections (BSI) caused by yeast in England in 2022, as tracked by the SGSS. The incidence rate of BSI due to yeast increased slightly to 4.0 per 100,000 people, up from 3.8 per 100,000 in 2021. The three most frequently identified yeast species in blood samples were Candida albicans (40%), Nakaseomyces glabratus (previously known as Candida glabrata, 29%), and Candida parapsilosis (13%). Thus, the rising number of fungal infections is contributing to the growth of the onychomycosis treatment market.

The rising prevalence of diabetes is poised to drive the growth of the onychomycosis treatment market in the foreseeable future. Diabetes is a chronic medical condition characterized by elevated levels of blood glucose (blood sugar), increasing the likelihood of developing onychomycosis, elevating the risk of infection, and delaying the healing process. Topical and laser therapies play a crucial role in preventing complications and enhancing foot health, ultimately reducing the risk of subsequent infections. For example, in March 2021, a report from the LSU AgCenter, a Louisiana-based agricultural research center, indicated that in 2021, the United States had over 34.2 million individuals living with diabetes, and it is projected that the global population affected by diabetes will surge to 578 million by the year 2030. As a result, the growing prevalence of diabetes is a key driver behind the expansion of the onychomycosis treatment market.

Prominent companies operating in the onychomycosis treatment market are placing a strong emphasis on the development of novel products, like MOB-015, and obtaining approvals from regulatory agencies as part of their strategy to secure a competitive edge within the market. For instance, Moberg Pharma AB, a pharmaceutical company based in Sweden, which successfully obtained approval for MOB-015 from the European Union to treat mild to moderate fungal nail infections in adults. This EU approval marks a significant milestone as the first global marketing authorization for this innovative onychomycosis medication. The approval is underpinned by two Phase 3 trials supporting MOB-015, which demonstrated enhanced mycological cure rates (76% compared to up to 42% for comparators) and a substantially higher overall cure rate than the vehicle, all achieved without any occurrence of serious adverse effects. MOB-015, a topical terbinafine formulation, enables the delivery of effective terbinafine concentrations to the nail and nail bed without the associated systemic exposure risk associated with oral terbinafine treatments.

In August 2023, Karo Healthcare AB, a Swedish consumer healthcare company, completed the acquisition of Lamisil from Haleon PLC for an approximate sum of $297.86 million. This strategic move to acquire Lamisil significantly enriches Karo Healthcare's portfolio of over-the-counter (OTC) products and extends its offerings within the field of foot health. Furthermore, this transaction serves to broaden Karo's global footprint and augment its market presence in the realm of Foot Health. Lamisil, a well-known oral antifungal medication primarily utilized for the treatment of onychomycosis, was previously held by Haleon PLC, a UK-based consumer healthcare enterprise.

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the onychomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The onychomycosis treatment market consists of revenues earned by entities by providing combination therapy, nail debridement and Carbon dioxide ablative laser treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The onychomycosis treatment market also includes sales of griseofulvin, terbinafine, itraconazole, ketoconazole and more. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Onychomycosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on onychomycosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for onychomycosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The onychomycosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types
• 2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy
• 3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Companies Mentioned: Johnson & Johnson Services Inc.; Bristol-Myers Squibb Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Hetero Drugs Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Onychomycosis Treatment Market Characteristics

3. Onychomycosis Treatment Market Trends And Strategies

4. Onychomycosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Onychomycosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Onychomycosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Onychomycosis Treatment Market Growth Rate Analysis
• 5.4. Global Onychomycosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Onychomycosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Onychomycosis Treatment Total Addressable Market (TAM)

6. Onychomycosis Treatment Market Segmentation

• 6.1. Global Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Sublingual Onychomycosis
• White Superficial Onychomycosis
• Proximal Sublingual Onychomycosis
• Candida Onychomycosis
• Other Types
• 6.2. Global Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Laser Therapy
• Photodynamic Therapy
• 6.3. Global Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 0 To 18 Years
• 18 To 39 Years
• 40 To 64 Years
• 65 Years And Above
• 6.4. Global Onychomycosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

7. Onychomycosis Treatment Market Regional And Country Analysis

• 7.1. Global Onychomycosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Onychomycosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Onychomycosis Treatment Market

• 8.1. Asia-Pacific Onychomycosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Onychomycosis Treatment Market

• 9.1. China Onychomycosis Treatment Market Overview
• 9.2. China Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Onychomycosis Treatment Market

• 10.1. India Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Onychomycosis Treatment Market

• 11.1. Japan Onychomycosis Treatment Market Overview
• 11.2. Japan Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Onychomycosis Treatment Market

• 12.1. Australia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Onychomycosis Treatment Market

• 13.1. Indonesia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Onychomycosis Treatment Market

• 14.1. South Korea Onychomycosis Treatment Market Overview
• 14.2. South Korea Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Onychomycosis Treatment Market

• 15.1. Western Europe Onychomycosis Treatment Market Overview
• 15.2. Western Europe Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Onychomycosis Treatment Market

• 16.1. UK Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Onychomycosis Treatment Market

• 17.1. Germany Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Onychomycosis Treatment Market

• 18.1. France Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Onychomycosis Treatment Market

• 19.1. Italy Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Onychomycosis Treatment Market

• 20.1. Spain Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Onychomycosis Treatment Market

• 21.1. Eastern Europe Onychomycosis Treatment Market Overview
• 21.2. Eastern Europe Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Onychomycosis Treatment Market

• 22.1. Russia Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Onychomycosis Treatment Market

• 23.1. North America Onychomycosis Treatment Market Overview
• 23.2. North America Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Onychomycosis Treatment Market

• 24.1. USA Onychomycosis Treatment Market Overview
• 24.2. USA Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Onychomycosis Treatment Market

• 25.1. Canada Onychomycosis Treatment Market Overview
• 25.2. Canada Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Onychomycosis Treatment Market

• 26.1. South America Onychomycosis Treatment Market Overview
• 26.2. South America Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Onychomycosis Treatment Market

• 27.1. Brazil Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Onychomycosis Treatment Market

• 28.1. Middle East Onychomycosis Treatment Market Overview
• 28.2. Middle East Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Onychomycosis Treatment Market

• 29.1. Africa Onychomycosis Treatment Market Overview
• 29.2. Africa Onychomycosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Onychomycosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Onychomycosis Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Onychomycosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Onychomycosis Treatment Market Competitive Landscape
• 30.2. Onychomycosis Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hetero Drugs Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Onychomycosis Treatment Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Limited
• 31.2. Cadila Pharmaceuticals Ltd.
• 31.3. Dr. Reddys Laboratories Ltd.
• 31.4. Intas Pharmaceuticals Limited
• 31.5. Cipla Limited
• 31.6. Lupin Limited
• 31.7. Glenmark Pharmaceuticals Ltd.
• 31.8. Aurobindo Pharma Limited
• 31.9. Alkem Laboratories Limited
• 31.10. Jubilant Life Sciences Ltd.
• 31.11. Torrent Pharmaceuticals Ltd.
• 31.12. Mankind Pharma Ltd.
• 31.13. Biocon Limited
• 31.14. Emcure Pharmaceuticals Limited
• 31.15. Alembic Pharmaceuticals Ltd.

32. Global Onychomycosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Onychomycosis Treatment Market

34. Recent Developments In The Onychomycosis Treatment Market

35. Onychomycosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Onychomycosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Onychomycosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Onychomycosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer